Dana-Farber Cancer Institute: Waldenstrom Macroglobulinemia trials

The registry lists 26 Waldenstrom Macroglobulinemia studies with Dana-Farber Cancer Institute as lead sponsor. 2 are open to participants now and 17 have results posted.

Phase 1 3Phase 2 20Phase 4 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• Ibrutinib + Venetoclax in Untreated WMActive, not recruitingNCT04273139Phase 2Results posted
• A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's MacroglobulinemiaTerminatedNCT03225716Phase 1Results posted
• A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström MacroglobulinemiaCompletedNCT03187262Phase 2Results posted
• Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström MacroglobulinemiaCompletedNCT02677324Phase 2Results posted
• Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome SequencingCompletedNCT02604511Phase 2Results posted
• Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström MacroglobulinemiaTerminatedNCT02439138Phase 2Results posted
• Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaCompletedNCT02400437Phase 2Results posted
• Ibrutinib (PCI-32765) in Waldenstrom's MacroglobulinemiaCompletedNCT01614821Phase 2Results posted
• Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's MacroglobulinemiaCompletedNCT01470196Phase 2Results posted
• Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaTerminatedNCT01125293Phase 1/2Results posted
• Everolimus (RAD001) in Primary Therapy of Waldenstrom's MacroglobulinemiaCompletedNCT00976248Phase 2Results posted
• LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's MacroglobulinemiaCompletedNCT00936611Phase 2Results posted
• Simvastatin in Waldenstrom's MacroglobulinemiaTerminatedNCT00575965Phase 2Results posted
• Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)CompletedNCT00422799Phase 2Results posted
• Perifosine in Patients With Relapsed/Refractory Waldenstrom's MacroglobulinemiaCompletedNCT00422656Phase 2Results posted
• Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms MacroglobulinemiaCompletedNCT00250926Phase 2Results posted
• CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's MacroglobulinemiaTerminatedNCT00142168Phase 2Results posted
• Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaActive, not recruitingNCT05734495Phase 2
• ERK 1/2 Signaling in Ibrutinib Resistant B-cell MalignanciesWithdrawnNCT04043845Phase 1
• Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related DisordersActive, not recruitingNCT01177527
• Sildenafil Citrate in Waldenstrom's MacroglobulinemiaCompletedNCT00165295Phase 2
• Phase II Study of Campath-1H Antibody to Treat Waldenstrom's MacroglobulinemiaCompletedNCT00142181Phase 2
• Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's MacroglobulinemiaCompletedNCT00142155Not applicable
• Bortezomib (Velcade) in Waldenstrom's MacroglobulinemiaCompletedNCT00142129Phase 2